Best possible treatment from day 1
Biovica develops and commercializes blood based assays for prognosis and monitoring of effect of targeted cancer treatments

Our objective is to enable best possible treatment for cancer patients from day one!

Anders Rylander
CEO
Biovica in Brief

• Develops biomarker assays for enabling personalized treatments for better outcome
• Biotech company in early commercial phase
• Listed on First North
• Market Cap ~ SEK 160 m
• Annual turnover of SEK 2.7 m
• Patented technology
Why invest in Biovica?

- Beneficial for cancer patients and payers
- Addresses an unmet need for personalized treatments within metastatic cancer
- Large market potential of SEK 6 billion for metastatic breast cancer area in US & Europe
- Strong scientific collaborations and evidence
- Early commercial phase, next milestone FDA application 2019

More info: http://biovica.com/investor-relations/analytiker/
The product DiviTum®

• Measures cell proliferation
• Implemented on standard platform
• Strong competitive position
DiviTum® a blood based biomarker assay

• Blood based
• Monitor and predict treatment response in cancer therapy
• ELISA – standardized platform
• CE-marked
• Patented method and kit
DiviTum® provides early response to whether or not the patient's cancer treatment is effective.

DiviTum® measures cell proliferation rate for faster evaluation of cancer treatment effects.

References: See http://biovica.com/technology/publications/
DiviTum® - strong position in regards to competing / complementary technologies

**Imaging**
- Standard method for treatment evaluation
- Requires 3-4 months follow up time
- Example: PET/CT, MRI

**Biopsies**
- Tumor samples collected through a needle
- Invasive, not suitable for treatment monitoring
- Example: Ki-67 (proliferation marker)

**Blood based markers**
- Requires only blood sample – convenient for treatment monitoring
- No marker established as golden standard in breast cancer
- Example: CA 15-3 (breast cancer)
Unmet need and market

• First application – metastatic breast cancer (MBC)

• Potential of SEK 6 billion/year in US and Europe alone (MBC)

• Long term potential – standard marker for cancer treatment evaluation
There’s an unmet need for biomarkers for individualized cancer treatments

- Many treatment options
- Efficacy evaluation
- Treatment resistance
- Cost issues
- Time consuming diagnostics
Cost for cancer treatments exceeds USD 100 billion!

≥ 90% of new treatments are targeted or hormonals – Biovica focus area

Source: IQVIA Oncology cost report 2018
Biovica focuses primarily on metastatic breast cancer

Breast cancer

• 450,000 patients with metastatic breast cancer in US and Europe
• Market potential SEK 6 billion/year (US & Europe)
• Additional potential: Research market, other metastatic cancers, local cancer, CDx, etc

*) Based on Globocan 2018-data
Strong Clinical Study Results for DiviTum®

- 16 articles, peer reviewed and published in oncology journals
- Results within major oncology areas (Breast, Lung, Gastro Intestinal, Blood malignancies)
- Ongoing program within breast cancer with world leading cancer institutes
DiviTum® - Strong evidence within breast cancer

<table>
<thead>
<tr>
<th>Stage</th>
<th>Early Breast Cancer</th>
<th>Locally Advanced disease</th>
<th>Metastatic disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>Metastatic Breast Cancer, Chemo therapy, 287 pat</td>
<td>TEX Metastatic Breast Cancer, 31 pat</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Early Breast Cancer, 161 pat</td>
<td>BRECA 80 pat</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>BRCA 80 pat</td>
<td>Early Breast Cancer, 161 pat</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Screening High Risk</td>
<td>Early Breast Cancer</td>
<td></td>
</tr>
</tbody>
</table>

Published
Presented

References: See http://biovica.com/technology/publications/
DiviTum® summary of results from published breast cancer studies, all with statistically significant results

<table>
<thead>
<tr>
<th>Study</th>
<th>Stage</th>
<th>#Pat</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA</td>
<td>High risk</td>
<td>80</td>
<td>DiviTum able to predict which high-risk-patients (BRCA-positive) that would develop cancer.</td>
</tr>
<tr>
<td>BC early</td>
<td>I, II</td>
<td>161</td>
<td>DiviTum able to predict risk for recurrence within 5 years.</td>
</tr>
<tr>
<td>TEX</td>
<td>III, IV</td>
<td>287</td>
<td>DiviTum prognostic for progression and survival. Better than CA 15-3 (golden standard marker breast cancer).</td>
</tr>
<tr>
<td>Wash-U</td>
<td>II, III</td>
<td>48</td>
<td>DiviTum able to assess changes caused by targeted treatment, 2 weeks after treatment start. Correlated to biopsy proliferation marker.</td>
</tr>
<tr>
<td>Pilot Prato</td>
<td>IV</td>
<td>31</td>
<td>DiviTum able to identify patients responding to hormonal treatment both before and after one month of treatment.</td>
</tr>
<tr>
<td>Lund</td>
<td>IV</td>
<td>142</td>
<td>DiviTum able to identify patients responding to 3 types of treatments both before and during treatment.</td>
</tr>
<tr>
<td>EFECT</td>
<td>IV</td>
<td>244</td>
<td>DiviTum able to identify patients responding to hormonal treatment (2nd line) both before and after one month of treatment.</td>
</tr>
<tr>
<td>7 studies</td>
<td>All stages</td>
<td>n=993</td>
<td></td>
</tr>
</tbody>
</table>

References: See http://biovica.com/technology/publications/
Ongoing metastatic breast cancer study program in collaboration with world-leading institutes

<table>
<thead>
<tr>
<th>Study</th>
<th>Stage</th>
<th>#Pat</th>
<th>Endpoints</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>PYTHIA IV</td>
<td>IV</td>
<td>120</td>
<td>TK-activity for targeted drug response</td>
<td>2019</td>
</tr>
<tr>
<td>PREDIX III</td>
<td>III</td>
<td>200</td>
<td>TK for targeted drug response and survival</td>
<td>2020</td>
</tr>
<tr>
<td>FELINE III</td>
<td>III</td>
<td>120</td>
<td>TK for targeted drug response and correlation to other biomarkers</td>
<td>2019</td>
</tr>
<tr>
<td>City of Hope, LA IV</td>
<td>IV</td>
<td>18</td>
<td>Pilot two targeted drugs, response</td>
<td>2019</td>
</tr>
<tr>
<td>University of Pennsylvania IV</td>
<td>28</td>
<td>Pilot chemo &amp; targeted drug, response</td>
<td>2019</td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins IV</td>
<td>IV</td>
<td>100</td>
<td>Biomarker for targeted drug resistance</td>
<td>2020</td>
</tr>
</tbody>
</table>

**6 studies**  
**III-IV**  
**n=586**
Road to market

- Early commercial phase
- 4 main work flows
  - Clinical development
  - Product development
  - Regulatory approval
  - Market access
- Next milestone: FDA application
Biovica go-to market plan

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>1st MBC</td>
<td>DiViTum CE</td>
<td>CE</td>
<td>Sales research market</td>
</tr>
<tr>
<td>2015</td>
<td>1st targeted MBC</td>
<td>DiViTum FDA</td>
<td>FDA Pre-sub</td>
<td>Commercial partnerships</td>
</tr>
<tr>
<td>2017</td>
<td>MBC Regulatory &amp; Demand</td>
<td></td>
<td>Supp.#1</td>
<td>Reimbursement</td>
</tr>
<tr>
<td>2019</td>
<td>Targeted Lung &amp; GI Pilot</td>
<td></td>
<td>Supp.#2</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Team

• Experience of taking biomarker assays and oncology products to market

• Experience of FDA and reimbursement processes

• Committed, a majority of key people are Biovica shareholders
Experienced management team

Anders Rylander
CEO
Holdings: 3 575 640 A-shares and 360 956 B-shares

Cecilia Driving
CFO
Holdings: 9 000 B-shares and 40 000 warrants

Karin Mattsson, Ph.D
R&D Director
Holdings: 1 000 B-shares and 40 000 warrants

Pontus Nobreus
Business Dev. Director
Holdings: 6 000 B-shares and 20 000 warrants

Mattias Bergqvist
Clinical Dev. Director
Holdings: 106 560 B-shares and 20 000 warrants

Wing Cheng, Ph.D
Market Access & QA Director
Holdings: 2 500 B-shares and 20 000 warrants

Adam Germunder
Operations Director
Holdings: 3 600 B-shares and 20 000 warrants
Board of Directors

Göran Brorsson
Chairman
Holdings: 73 245 A-shares,
116 000 B-shares, 3 000 warrants

Maria Holmlund
Board Member
Holdings: 9 750 B-shares

Jesper Söderqvist
Board Member
Holdings: 41 085 A-shares,
32 700 B-shares, 3 000 warrants

Jarl Ulf Jungnelius
Board Member
Holdings: 0

Anders Rylander
Board Member
Holdings: 3 575 640 A-shares
and 360 956 B-shares
Best possible treatment from day 1